Phaseline

Targets › DHEAS

DHEAS: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Genitourinary; next expected readout Jan 2027.

Open in Phaseline: the race on DHEAS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jiangxi University of Traditional Chinese MedicineBushen Yiqi Formula
Adrenal steroid hormone precursor; androgen receptor agonist
DHEASPhase 1Diminished Ovarian ReserveJan 2027

Conditions

Diminished Ovarian Reserve (2)

Modalities

small molecule (1)

Companies

Jiangxi University of Traditional Chinese Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.